Cellular Biomedicine Group Inc. (CBMG)

Trade CBMG now with
12/30/2019 8:43:28 AM Cellular Biomedicine Announces Engagement Of Independent Advisors To Evaluate Proposal Submitted By CEO-led Consortium
11/11/2019 10:01:55 AM Cellular Biomedicine Receives US$19.50/shr Preliminary Non-Binding Going Private Proposal
10/2/2019 8:45:57 AM CBMG Enters Lease Agreement To Build An Approximately 22,000 Square Foot Facility In Rockville, Maryland
6/17/2019 7:02:36 AM Cellular Biomedicine Announces First Patient Dosing In Phase I Clinical Trial Of Anti-CD20 CAR-T For Lymphoma In China
4/23/2019 8:32:18 AM Cellular Biomedicine Group Upgraded To NASDAQ Global Select Market
3/21/2019 9:02:10 AM Cellular Biomedicine Announces Pricing Of Underwritten Public Offering Of 1.03 Mln Shares At $17.00/shr
3/20/2019 4:01:56 PM Cellular Biomedicine Group Announces Proposed Follow-on Offering Of Common Stock
1/17/2019 6:05:12 AM CBMG: AlloJoin Therapy For KOA Becomes First Stem Cell Drug Application Approved In China For Phase II Clinical Trials
1/8/2019 7:42:54 PM Cellular Biomedicine Group Initiates Patient Recruitment For Clinical Trial In Anti-BCMA CAR-T Therapy
12/18/2018 7:31:47 AM Cellular Biomedicine Group Appoints Stephan Grupp As Member Of Scientific Advisory Board
11/6/2018 7:09:14 AM Cellular Biomedicine Group Q3 Loss/shr $0.72 Vs. Loss/shr $0.43 Last Year
9/27/2018 7:37:09 AM Cellular Biomedicine Enters Into Strategic Licensing And Collaboration Deal With A Global Leader In CAR-T Cell Therapy
8/8/2018 7:34:14 AM Cellular Biomedicine Group Q2 Net Loss Allocable To Common Stock Holders $9.2 Mln
5/8/2018 6:08:49 AM Cellular Biomedicine Q1 Net Loss Allocable To Common Stock Holders $8.5 Mln Vs Loss $6.2 Mln Last Year
3/16/2018 7:04:12 AM Cellular Biomedicine Announces Positive 48-Week Clinical Data Of AlloJoin HaMPC And KOA China Phase I Trial